Prognostic value of plasma von Willebrand factor and its cleaving protease ADAMTS13 in patients with atrial fibrillation

International Journal of Cardiology

Volumn 168, Issue 1, 2013, Pages 317-325

  Freynhofer, Matthias K ^a,b   Gruber, Susanne C ^a   Bruno, Veronika ^a   Höchtl, Thomas ^a   Farhan, Serdar ^a   Zaller, Vera ^c   Wojta, Johann ^b,c   Huber, Kurt ^a,b  

^a WILHELMINEN HOSPITAL   (Austria)

^b Ludwig Boltzmann Cluster for Cardiovascular Research   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

ADAMTS13; Atrial fibrillation; CHA2DS2VASc; CHADS2; von Willebrand factor

Indexed keywords

ACETYLSALICYLIC ACID; BIOLOGICAL MARKER; CLOPIDOGREL; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE FREE SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PAROXYSMAL HEART ATRIUM FIBRILLATION; PATHOPHYSIOLOGY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN CLEAVAGE; PROTEIN FUNCTION; RISK ASSESSMENT; SCORING SYSTEM; THROMBOEMBOLISM; THROMBOSIS PREVENTION; TRANSIENT ISCHEMIC ATTACK;

ADAMTS13; ATRIAL FIBRILLATION; CHA(2)DS(2)VASC; CHADS(2); VON WILLEBRAND FACTOR;

ADAM PROTEINS; AGED; ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; VON WILLEBRAND FACTOR;

EID: 84883774037     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.09.056     Document Type: Article

References (43)

1. P.A. Wolf, R.D. Abbott, and W.B. Kannel Atrial fibrillation as an independent risk factor for stroke: the Framingham study Stroke 22 1991 983 988
2. E.J. Benjamin, P.A. Wolf, and R.B. D'Agostino Impact of atrial fibrillation on the risk of death: the Framingham heart study Circulation 98 1998 946 952
3. R.G. Hart, L.A. Pearce, and M.I. Aguilar Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation Ann Intern Med 146 2007 857 867
4. B.F. Gage, A.D. Waterman, and W. Shannon Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation JAMA 285 2001 2864 2870
5. G.Y. Lip, R. Nieuwlaat, and R. Pisters Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro heart survey on atrial fibrillation Chest 137 2010 263 272
6. A.J. Camm, P. Kirchhof, and G.Y. Lip Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Eur Heart J 31 2010 2369 2429
7. G.Y. Lip, and D.A. Lane Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients? Am J Med 123 2010 785 789
8. U.M. Vischer von Willebrand factor, endothelial dysfunction, and cardiovascular disease J Thromb Haemost 4 2006 1186 1193
9. M.K. Freynhofer, V. Bruno, and J. Wojta The role of platelets in athero-thrombotic events Curr Pharm Des 18 2012 5197 5214
10. A.K. Chauhan, J. Kisucka, and A. Brill ADAMTS13: a new link between thrombosis and inflammation J Exp Med 205 2008 2065 2074
11. T. Uemura, K. Kaikita, and H. Yamabe Changes in plasma von Willebrand factor and ADAMTS13 levels associated with left atrial remodeling in atrial fibrillation Thromb Res 124 2009 28 32
12. N. Ammash, E.A. Konik, and R.D. McBane Left atrial blood stasis and von Willebrand factor-ADAMTS13 homeostasis in atrial fibrillation Arterioscler Thromb Vasc Biol 31 2011 2760 2766
13. D.S. Conway, L.A. Pearce, and B.S. Chin Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation Circulation 107 2003 3141 3145
14. V. Roldan, F. Marin, and B. Muina Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients J Am Coll Cardiol 57 2011 2496 2504
15. M.K. Freynhofer, V. Bruno, and R. Jarai Levels of von Willebrand factor and ADAMTS13 determine clinical outcome after cardioversion for atrial fibrillation Thromb Haemost 105 2011 435 443
16. V. Fuster, L.E. Ryden, and D.S. Cannom ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society Circulation 114 2006 e257 e354
17. J.D. Easton, J.L. Saver, and G.W. Albers Definition and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease. The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists Stroke 40 2009 2276 2293
18. J. Heeringa, D.S. Conway, and D.A. van der Kuip A longitudinal population-based study of prothrombotic factors in elderly subjects with atrial fibrillation: the Rotterdam study 1990-1999 J Thromb Haemost 4 2006 1944 1949
19. A. Alonso, W. Tang, and S.K. Agarwal Hemostatic markers are associated with the risk and prognosis of atrial fibrillation: the ARIC study Int J Cardiol 155 2010 217 222
20. Z.M. Ruggeri Platelets in atherothrombosis Nat Med 8 2002 1227 1234
21. A.J. Reininger Function of von Willebrand factor in haemostasis and thrombosis Haemophilia 14 Suppl. 5 2008 11 26
22. B. Savage, E. Saldivar, and Z.M. Ruggeri Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor Cell 84 1996 289 297
23. N. Methia, P. Andre, and C.V. Denis Localized reduction of atherosclerosis in von Willebrand factor-deficient mice Blood 98 2001 1424 1428
24. C. Kleinschnitz, M. Pozgajova, and M. Pham Targeting platelets in acute experimental stroke: impact of glycoprotein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleeding Circulation 115 2007 2323 2330
25. W. Bergmeier, C.L. Piffath, and T. Goerge The role of platelet adhesion receptor GPIbalpha far exceeds that of its main ligand, von Willebrand factor, in arterial thrombosis Proc Natl Acad Sci U S A 103 2006 16900 16905
26. H. Ulrichts, K. Silence, and A. Schoolmeester Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs Blood 118 2011 757 765
27. T.C. Nichols, C.M. Samama, and D.A. Bellinger Function of von Willebrand factor after crossed bone marrow transplantation between normal and von Willebrand disease pigs: effect on arterial thrombosis in chimeras Proc Natl Acad Sci U S A 92 1995 2455 2459
28. D.C. Felmeden, A.D. Blann, and C.G. Spencer A comparison of flow-mediated dilatation and von Willebrand factor as markers of endothelial cell function in health and in hypertension: relationship to cardiovascular risk and effects of treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial Blood Coagul Fibrinolysis 14 2003 425 431
29. V. Schachinger, M.B. Britten, and A.M. Zeiher Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease Circulation 101 2000 1899 1906
30. T. Neunteufl, S. Heher, and R. Katzenschlager Late prognostic value of flow-mediated dilation in the brachial artery of patients with chest pain Am J Cardiol 86 2000 207 210
31. S. Moncada, and A. Higgs The l-arginine-nitric oxide pathway N Engl J Med 329 1993 2002 2012
32. T.N. Bongers, E.L. de Bruijne, and D.W. Dippel Lower levels of ADAMTS13 are associated with cardiovascular disease in young patients Atherosclerosis 207 2009 250 254
33. J.T. Crawley, D.A. Lane, and M. Woodward Evidence that high von Willebrand factor and low ADAMTS-13 levels independently increase the risk of a non-fatal heart attack J Thromb Haemost 6 2008 583 588
34. M. Fukuchi, J. Watanabe, and K. Kumagai Increased von Willebrand factor in the endocardium as a local predisposing factor for thrombogenesis in overloaded human atrial appendage J Am Coll Cardiol 37 2001 1436 1442
35. T. Gombos, V. Mako, and L. Cervenak Levels of von Willebrand factor antigen and von Willebrand factor cleaving protease (ADAMTS13) activity predict clinical events in chronic heart failure Thromb Haemost 102 2009 573 580
36. S. Goto, D.L. Bhatt, and J. Rother Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis Am Heart J 156 2008 855 863 [63 e2]
37. J.J. Hulstein, P.G. de Groot, and K. Silence A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B Blood 106 2005 3035 3042
38. M. Arya, B. Anvari, and G.M. Romo Ultralarge multimers of von Willebrand factor form spontaneous high-strength bonds with the platelet glycoprotein Ib-IX complex: studies using optical tweezers Blood 99 2002 3971 3977
39. J.F. Dong, J.L. Moake, and L. Nolasco ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions Blood 100 2002 4033 4039
40. S. Moriguchi-Goto, A. Yamashita, and N. Tamura ADAMTS-13 attenuates thrombus formation on type I collagen surface and disrupted plaques under flow conditions Atherosclerosis 203 2009 409 416
41. A. Kourliouros, I. Savelieva, and A. Kiotsekoglou Current concepts in the pathogenesis of atrial fibrillation Am Heart J 157 2009 243 252
42. R. Ross Atherosclerosis - an inflammatory disease N Engl J Med 340 1999 115 126
43. B.Q. Zhao, A.K. Chauhan, and M. Canault von Willebrand factor-cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke Blood 114 2009 3329 3334